DENVER, Colo., Oct 26, 2023 (www.247marketnews.com)- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) reported, this morning, improved survival in murine models bearing human glioblastoma multiforme (GBM) tumors treated with its lead therapeutic candidate, TTX-MC138. In this study, mice implanted with human GBM tumors treated with TTX-MC138 survived significantly longer than those in the control group.
TransCode Therapeutics is trading at $0.43, up $0.06 (+15.90%), on 561.6K premarket shares traded.
Its 52-week range is $0.301 to $23.40. It hit a new 52-week low on Monday and is trying to reverse that downtrend. Its next key inflection point is 52-cents.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.